TPT1 and cancer: Since our results provided a rationale that targeting TCTP to reinforce multiple steps in anti-cancer immune events, thereby overcoming immunotherapy resistance, we screened clinically available TCTP-targeting agents such as DHA, rapamycin, sertraline, and thioridazine.